19165-26-5Relevant articles and documents
-
Johnson,Katner
, p. 1455,1459 (1965)
-
A novel organic reaction leading to new 2-N-substituted benzoic acid ion-pair. A combination of physicochemical and theoretical calculations approaches
Abderrahim, Raoudha.,Akriche, Sameh.,Amor, Abir. Ben Hadj,Arfaoui, Youssef.
, (2020)
The 2-aminobenzimidazole (ABZ)-2-N-propanoyl benzoic acid 1 which is an intermediate of synthesis of various heterocyclic compounds was synthesized. The structure of 1 was confirmed by FT-IR, NMR (1D and 2D) spectra and XRD. The molecular structure of compound 1 was characterized by single-crystal X-ray structure determination and theoretical calculations based on DFT, HF and MP2 methods. The NBO analysis was used mainly in order to study the influence of electronic delocalization on the mechanism. Experimental, DFT, HF and MP2/6-31G(d) optimized bond lengths, bond angles and hydrogen bonding for the structure are studied also. The structure analysis shows that the 3D-supramolecular architecture of 1 is stabilized by means six-(S6) intramolecular and eight-(R22(8)) membered intermolecular hydrogen bonds, together with extensive C—H…O and C—H…π interactions between the carboxylate anion and the 2-aminobenzimidazolium cation. Furthermore, parameters derived from density functional theory in a local sense, in particular the softness and Fukui function were used to interpret and predict the mechanism of the reaction.
Casein kinase 1[epsilon] inhibitor, pharmaceutical composition and application thereof
-
Paragraph 0207; 0209, (2021/01/11)
The invention discloses a novel substituted pyrazolopyrimidine compound for inhibiting the activity of casein kinase 1[epsilon] (CK1[epsilon]), a stereoisomer or a stereoisomer mixture of the novel substituted pyrazolopyrimidine compound, a pharmaceutically acceptable salt or solvate of the novel substituted pyrazolopyrimidine compound, and application of the compound to preparation of medicine for treating diseases, disorders or symptoms benefiting from the inhibition of the activity of casein kinase 1[epsilon] (CK1[epsilon]). The compound has inhibitory activity on CK1[epsilon] kinase, OCI-LY10 cells and Karpas299 cells, shows good anti-tumor activity in an OCI-LY10 subcutaneous xenogeneic model, shows excellent synergistic anti-tumor activity when being combined with a BTK inhibitor, has good pharmacokinetic properties, and can be applied to treatment of diseases, disorders or symptoms, including cancers, autoimmune diseases and the like, which benefit from inhibition of casein kinase 1[epsilon] activity, alone or in combination with other drugs.
Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl/ethyl-4H-quinazolin-3-yl)-urea
Kashaw, Sushil K.,Kashaw, Varsha,Mishra, Pradeep,Jain,Stables
experimental part, p. 4335 - 4343 (2009/12/24)
Several new 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl/ethyl-4H-quinazolin-3-yl)-urea were synthesized and screened for anticonvulsant, CNS depressant and sedative-hypnotic activity in the mice. After i.p. injection to mice at doses of 30, 100, and 300 mg/kg body weight synthesized compounds were examined in the maximal electroshock induced seizures (MES) and subcutaneous pentylenetetrazole (scPTZ) induced seizure models in mice. Spectroscopic data and elemental analysis were consistent with the newly synthesized compounds. The neurotoxicity was assessed using the rotorod method. Compounds E1, E6, E9, E12, P3, P4 and P6 were found to be active in the MES screen whereas E1, P4, P6 and P11 were found to be active in the scPTZ screen. All except E6, E11 and P6 showed more than 50% decrease in locomotor activity at 1 h of compound administration via actophotometer screen. CNS depressant activity screened with the help of the forced swim method resulted into some potent compounds. All the compounds were found to exhibit potent CNS depressants activity as indicated by increased immobility time. It can be concluded that newly synthesized compounds possessed promising CNS activities.
